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ABSTRACT 
The pathogenesis of metabolic syndrome is multifactorial and hormones play an essential role 
in its development. Estrogen loss in postmenopausal women has been linked to several 
features of metabolic syndrome, while estrogen replacement therapy reverses these 
pathological and metabolic features. However, estrogen replacement therapy is associated 
with adverse effects including breast cancer and coagulopathy. Therefore, identification of 
the molecular mechanisms of estrogen’s beneficial effects would give the possibility to target 
them directly and to prevent the undesirable side effects. In this study, administration of 17β-
estradiol (E2) in a perimenopausal mouse model maintained on a high fat diet (HFD) for 10 
months results in improved glycemic control and body weight reduction, in association with 
multiple molecular mechanisms in the visceral adipose tissue (Paper 1) and liver (Paper 2) 
without suppression of inflammatory mediators in these organs (Paper 3).  
In visceral adipose tissue, E2 administration results in an anti-obesogenic effect and a 
reduction of adipocyte size in parallel with molecular mechanisms, including the activation of 
the lipolytic enzyme pnpla2, the suppression of lipogenic gene expression possibly through 
downregulating the expression levels of the nuclear receptor nr2c2/tr4, and the induction of 
brown adipose tissue-specific gene expression via E2-dependent alterations in methylation 
levels (Paper 1). In liver, E2 treatment induces activation of hepatic AMPK, which results in 
the suppression of hepatic lipogenesis via inhibition of NR2C2/TR4, and in the inhibition of 
gluconeogenesis through suppression of transcript levels of the gluconeogenic g6pc; E2 
treatment also normalizes hepatic triglycerides through the suppression of lipogenesis and the 
activation of triglyceride mobilization; the summative effect of these events results in 
improvements in hepatic insulin signaling (Paper 2). 
E2 induces increased expression levels of pro-inflammatory mediators in the visceral adipose, 
which does not impact upon the positive actions of E2 on body weight, fasting blood glucose 
levels, and glycemic control (Paper 3). The reductions induced by E2 in the plasma levels of 
adiponectin, and in its mRNA levels in adipose tissue, could explain the continued elevated 
expression levels of these mediators. Tracing the events of metabolic pathogenesis due to 
ovariectomy-related estrogen loss in an ovariectomized mouse model shows that estrogen 
signaling appears to suppress features of hepatic insulin resistance resulting from short-term 
HFD exposure by opposing the continuous accumulation of hepatic triglycerides, and via 
reduced expression levels of gluconeogenic genes (Paper 4). Ovariectomy resulted in weight 
gain, elevation of fasting blood glucose levels, increased hepatic triglycerides and increases in 
expression levels of nr2r2/tr4 and the pro-inflammatory tlr2, independently of dietary 
intervention.  
In conclusion, the current study highlights significant molecular mechanisms responsible for 
the effects of estrogen in relation to features of metabolic syndrome, giving the possibility to 
target them directly and to prevent the undesirable side effects of systemic E2 treatment. 
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1 INTRODUCTION 
1.1 HORMONES AND HORMONE RECEPTORS 
Integration between the endocrine and nervous systems is essential for regulation and 
coordination of biological process such as growth, differentiation, metabolism and 
reproduction [1]. Via neurotransmitters, the nervous system controls various rapid and 
localized effects, while the endocrine system acts through hormones to produce generalized 
effects on the whole body. Disruption of the endocrine system due to loss of hormones 
results in pathological conditions [1], and replacement therapy is one of the main 
pharmacological strategies to reverse the pathogenesis of these pathological conditions.  
Hormones are chemical messengers which are synthesized and produced by glands, and 
which are carried through blood to distant tissues to exert specific biological functions. 
There are four chemical categories of hormones: amino acid derivatives, fatty acid 
derivatives, polypeptides and steroid hormones.  Hormones exert their actions through 
binding to specific receptors in the target tissue. The receptors are expressed either on 
membranes, in which case they are known as membrane receptors, or intracellularly, and 
known as intracellular receptor [2]. 
Hormones with a hydrophilic (water-soluble) nature, such as peptide hormones, react with 
membrane-bound receptors and act through the activation of second messengers which 
regulate the function of proteins and transcription factors (Figure 1). Hydrophobic (lipid-
soluble) hormones, unlike hydrophilic hormones, can cross the phospholipid layer of cell 
membranes and interact with intracellular receptors. Hydrophobic hormones, such as 
steroids, bind to intracellular receptors, often resulting in the regulation of transcription of 
specific genes (Figure 2).  
 
Figure 1: Hydrophilic hormones (CC BY 3.0 by OpenStax CNX, https://courses.lumenlearning.com/ap2/chapter/hormones/) 
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Figure 2: Hydrophobic hormones (CC BY 3.0 by OpenStax CNX, https://courses.lumenlearning.com/ap2/chapter/hormones/) 
 
1.2 ESTROGENS  
Estrogens are a steroid compounds derived from cholesterol which function as a primary 
sex hormone in females. However, estrogens are found also in males and control sexual 
behaviors. Moreover, during the few last decades, estrogens have been linked to non-gender 
effects beyond the induction of female secondary sexual characteristics and the control of 
male sexual behaviors. Estrogens are reported to exert direct or indirect regulatory roles on 
growth, differentiation and function in different tissues, including the brain, bone, adipose 
tissue, glands and cardiovascular systems [3]. There are three major types of estrogens: 
estrone (E1), 17β-estradiol (E2) and estriol (E3). Biochemically, aromatase cytochrome 
P450 is the enzyme which converts androstenedione to E1, after which E1 is converted to 
E2. As a precursor for sexual steroids, androstenedione is converted to testosterone which is 
ultimately aromatized to E2 [4].  
1.2.1 Estrogen receptors 
Estrogen receptors (ER) exist as two isoforms: ERα and ERβ. They are nuclear receptors 
which are known as ligand-activated transcription factors. ERs have a structure typical of 
nuclear receptors, consisting of five domains. Each domain represents a specific function, 
many of which are known [5] (Figure 3): an N-terminal A/B domain, a DNA binding C 
domain, domain D, domain E, and a C-terminal F domain. The A/B domain activates the 
transcription of genes independently of ligand binding, while the E domain is the ligand-
binding domain. The D domain is a hinge region between the C DNA-binding domain and 
the E domain, which is responsible for ligand binding. The F domain is highly variable 
between nuclear receptors, and has been reported to stimulate and suppress transcription 
[6]. Transcriptional activity of ERα is mediated by both the A/B domain, which is also 
known as activation function 1 (AF-1), and the E domain, also called activation function 2 
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(AF-2), while that ERβ-mediated transactivation is mediated to a greater degree through 
AF-2, with less involvement of AF-1 [7]. 
ERα and ERβ are expressed in many tissues in males and females, including the ovaries, 
testes, prostate, liver, adipose tissue, hypothalamus, brain, muscle, pituitary gland, vascular 
endothelium and bone marrow. However, the ERα/ERβ ratio is variable in different tissues 
and usually localized in specific cell type or histological layer when they are expressed in 
the same tissue [8].  
 
Figure 3: Nuclear receptor (CC BY-SA 3.0 by Boghog2, https://commons.wikimedia.org/wiki/File:Nuclear_Receptor_Structure.png) 
 
1.2.2 Mechanisms of estrogen actions 
E2 exerts its action via genomic and non-genomic mechanisms with different pathways [9, 
10].  
Genomic mechanisms:  
The first genomic mechanism of estrogen action is a conventional mechanism in which 
activation of ER by estrogen leads to its dissociate from heat-shock protein, which normally 
keeps ER in an inactive form [11]. Consequently, ER is translocated into the nucleus and 
binds to estrogen response elements (EREs) in the promoters of target genes, leading to 
subsequent activation or inhibition of transcription [9, 10] .   
The second genomic mechanism is a ligand-independent mechanism during which 
intracellular kinase pathways are activated, leading to the phosphorylation and activation of 
ER at EREs in gene promoters in a ligand-independent style [10].  
The third genomic mechanism is ERE-independent, in which estrogen-ER complexes 
mediate the transcription of genes containing alternative response elements through 
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combination with other DNA-bound transcription factors which can associate with the 
activated ER, leading to an up-regulation of gene expression [10].  
Non-genomic mechanism: 
In this mechanism, no mRNA or protein is synthesized, and estrogens induce cellular 
effects independently of the transcriptional activity of ERs [12]. These effects involve rapid 
signaling which leads to different signal transduction pathways exclusively in estrogen-
sensitive cells [13].   
1.2.3 Approaches to study estrogen/estrogen receptor signaling 
There are different investigative approaches to study estrogen/estrogen receptor signaling in 
E2 target tissues in both physiological and pathological conditions. These approaches are 
classified as transgenic experimental models, non-transgenic experimental models and 
selective ERs modulators. 
Transgenic models are represented by genetically modified mice with disrupted ERα and/or 
ERβ, and are powerful tools for the assessment of estrogen/estrogen receptor signaling. 
ERα knockout (ERKO) mice were generated firstly in 1993 [14], while ERβ knockout 
(BERKO) mice were first described in 1998 [15, 16]. Furthermore, in 1998, another 
knockout model was created by disruption of the aromatase gene (ARKO mice) [17]. This 
mouse model expresses ERs, but cannot synthesize estrogens. Finally, organ-selective ER 
knockout mice have been created, such as liver-selective ERα knockout (LERKO) mice 
[18].   
Examples of non-transgenic models for the study of estrogen/estrogen receptor signaling 
include a long-term high fat diet (HFD) feeding model, which is a model of perimenopause 
and mimics aging-related menopause [19]. A second model is the ovariectomized (OVX) 
mice mouse, which mimics surgical menopausal hormone loss; sham-operated mice 
(SHAM) used as controls for this model, and are subjected to all of the surgical procedures 
as in OVX mice, except for ovariectomy [20]. 
Selective ER modulators (SERM) are a group of agonists and antagonists that bind to the 
ERs as ligands and lead to the activation or inhibition of transcription of target genes [21]. 
Tamoxifen is a SERM which is used as an antagonist treatment for breast cancer and as an 
agonist in the uterus and bone [22, 23]. Raloxifen is another SERM with a highly selective 
action which is used in the prevention of postmenopausal osteoporosis [24].  
1.3 ESTROGENS IN DIAGNOSTIC PATHOLOGY  
In clinical and anatomic pathology, estrogens are investigated to diagnose and follow up 
hypo- and hyper-estrogenism - associated diseases/conditions. 
1.3.1 Estrogen in diagnostic clinical pathology 
In clinical pathology, assessment of serum levels of E1, E2 or both is needed in a variety of 
lab diagnostic tests in males and females. The reference values are determined in 
correspondence with age and sex (Table 1) [25, 26].  
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Table1: References values of Estrone and Estradiol [25]  
Estrogen Age Sex Reference Value 
E1 2 weeks-18 years M Undetectable up to 10 pg/mL -60 
pg/mL 
E1 2 weeks-14.5 years F 29 pg/mL-200 pg/mL 
E1 Adult > 18 years M 10-60 pg/mL 
E1 Adult > 14 years F Premenopausal: 17-200 pg/mL 
Postmenopausal: 7-40 pg/mL 
E2 2 weeks-18 years M Undetectable up to 10 pg/mL-40 
pg/mL  
E2 2 weeks-14.5 years F 24 pg/mL-350 pg/mL 
E2 Adult > 18 years M 10-40 pg/mL 
E2 Adult > 14 years F Premenopausal: 15-350 pg/mL** 
Postmenopausal: <10 pg/mL 
   *Estrone and estradiol levels in 
newborns (1-14 days) are very high 
at birth but will drop to prepubertal 
levels 
“By permission of Mayo Foundation for Medical Education and Research.  All rights reserved.” 
The clinical significance of serum E1 and E2 assays includes but is not limited to [26-30]: 
(1) diagnosis and follow up of early and delayed puberty in females; (2) diagnosis and 
follow up of suspected disorders of sex steroid metabolism such as 17-alpha-hydroxylase 
deficiency and aromatase deficiency; (3) monitoring hormone replacement therapy in 
postmenopausal women or anti-estrogen therapy in cancers; (4) knowledge of serum E2 
levels is important to evaluate hypogonadism and oligomenorrhea; (5) E2 levels are crucial 
during in vitro fertilization to assess ovary and follicle development and ovulation; (6) E2 
levels are useful in evaluation of feminization in males and in diagnosis of estrogen-
producing tumors. 
Irregular menstrual cycles with high E2 levels are indicative of possible polycystic ovarian 
syndrome, or of the presence of androgen or estrogen producing tumors, while 
gynecomastia and high E1 and E2 levels in adult males are signs of liver disease or 
estrogen-androgen producing tumors e.g. prostate carcinoma [25]. 
1.3.2 Estrogen in histopathology 
In anatomic pathology and histopathology, steroid hormone receptor states in breast cancer 
are assessed mainly by semi-quantitative immunohistochemistry (IHC) and molecular 
expression profiling [31]. The clinical significance of assessment of ER levels is the 
substantial benefit of anti-estrogenic hormone therapy for ER-positive cancers, since more 
than 2/3 of ER-positive tumors are responsive to hormonal manipulation with good 
prognosis, compared to veer-negative tumors  [25, 31]. ER nuclear staining is interpreted as 
negative if reactive cells constitute less than 1% of the total, as focally positive if reactive 
cells constitute 1-10% of the total, and as positive if the reactive cells constitute more than 
10% of the total [25].  
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1.4 METABOLIC SYNDROME: MOLECULAR PATHOGENESIS AND 
ESTROGEN’S ROLE  
Metabolic syndrome is characterized by group of clinical manifestations include obesity, 
dyslipidemia, hypertension, insulin resistance and a pro-inflammatory state; affected 
patients with metabolic syndrome are at a high risk to develop type 2 diabetes (T2D) [32]. 
The pathogenesis of metabolic syndrome is multifactorial and hormones play an essential 
role in its development. Many clinical and basic research studies have reported a correlation 
between E2 and features of metabolic syndrome [33]. The pathogenesis of metabolic 
syndrome involves multiple mechanisms in different tissues that express ERs (Figure 4), 
including the brain, adipose tissue, liver, skeletal muscle and pancreas [34].  
 
Figure 4: Metabolic network and estrogen receptors 
 
1.4.1 Estrogen and the brain 
The brain has a role in regulation of metabolism through signals including hormones, 
cytokines and nutrients. In women, higher levels of E2 due to physiological or pathological 
conditions lead to decreased food intake and suppressed fat accumulation. Conversely, 
surgical or age-related menopause leads to an increase in food intake, an effect that is 
reversed by estrogen replacement therapy (ERT). Such observations show that E2 has an 
appetite-regulatory function in the central nervous system. Experimentally, intracranial 
injection of E2 in rats leads to loss of appetite. It is now known that these effects 
demonstrate an interactive axis between E2 and the hypothalamus [35] 
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E2 interacts with the hypothalamus through direct central mechanisms and indirect 
mechanisms. The central mechanisms involve activation of the pro-opiomelanocortin 
(POM) neurons, which express ERα and have anorexigenic effects through release of α-
melanocyte-stimulating hormone and cocaine & amphetamine-regulated transcript which 
target receptors of the melanocortin system, mainly isoforms 3 and 4 [36]. In ERKO mice, 
there is no upregulation of POM, which results in increased food intake [37]. Another 
central mechanism involves the activation of polypeptide neurons which express both ERα 
and ERβ and oppose the role of POM through release of polypeptides which prevent 
binding between α-melanocyte-stimulating hormone and receptors of the melanocortin 
system resulting in increased food intake. Both of POM and polypeptide neurons are part of 
the arcuate nucleus in the hypothalamus. ERα and/or ERβ are expressed in other 
hypothalamic areas involved in hunger and satiety, such as the lateral, ventromedial and 
dorsomedial hypothalamic regions. It is thought that the central actions of E2 on 
metabolism result from changes in feeding behavior rather than modulation of the 
metabolism of carbohydrates and lipids [34]. 
In addition to the central actions mentioned above, E2 also regulates peripheral hormones 
which regulate appetite and feeding through their actions in the brain. The regulation of 
these hormones by E2 is considered as an indirect mechanism through which E2 interacts 
with hypothalamus. These hormones include leptin, insulin, glucocorticoids and ghrelin. 
For instance, ERα and leptin receptor colocalize in the hypothalamus mainly in the arcuate 
nucleus [38], and E2 affects expression of leptin receptor, which results in increased 
hypothalamic sensitivity to leptin and ultimately affects body fat content [39]. E2 also 
affects body fat distribution by modulating insulin sensitivity and mRNA levels of both 
insulin and glucocorticoid receptors in the hypothalamus [40].  
1.4.2 Estrogen and adipose tissue 
Adipose tissue is a loose connective tissue which participates in metabolism, and has 
endocrine and immune roles. The size of the adipose tissue is considered as a mirror of the 
balance between intake and expenditure of energy [41, 42]. Central obesity and increased 
visceral adiposity are linked to pathogenesis and features of metabolic syndrome including 
insulin resistance, hypertension, and dyslipidemia. Clinically, the incidence of obesity and 
obesity-related disorders are higher in men, compared with women. However, after 
menopause, there is increased visceral fat mass and an increased risk for developing 
cardiovascular diseases and insulin resistance [43]  
In animal models, E2 treatment of female mice results in a reduction of body weight in 
association with decreased expression of lipogenic genes in adipose tissue [19]. Another 
study links E2-induced reductions in body fat in ovariectomized rats to activation of 
5’AMP-activated protein kinase (AMPK), increased uncoupling protein (UCP) and 
decreased the expression of resistin [44]. Moreover, the administration of tamoxifen as an 
anti-estrogen to ERKO and BERKO mice resulted in decreased GLUT4 expression in 
BERKO mice, but not in ERKO mice, suggesting that ERα regulates GLUT4 expression in 
adipose tissue [45]. Finally, ovariectomy of ERKO mice reduced body fat significantly, 
giving a conclusion that ERα and ERβ have opposite functions on fat metabolism [46]. 
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1.4.3 Estrogen and the liver 
The liver plays a major role in metabolism, possessing many functions including glycogen 
storage, plasma protein & clotting factor synthesis, hormone production and detoxification.  
Disturbances in liver function are related to insulin resistance, hyperglycemia and 
dyslipidemia. Liver function tests and lipid profiles reflect the activity of the liver. 
Abnormal lipid profiles, characterized by lower HDL levels and higher LDL and 
triglyceride levels, are more common in males, compared with females.  In addition, studies 
reveal that the incidence of fatty liver is higher in males than in females. However, after 
menopause, the frequency of abnormal lipid profiles and fatty liver disease increases in 
females, compared with males [47, 48]. In postmenopausal women, the consequences of 
ERT in postmenopausal women and E2 specifically increase HDL, decreased LDL, reduced 
triglycerides and lowered fasting glucose levels [49]. In contrast, anti-estrogen therapy 
leads to an abnormal lipid profile and steatosis, increasing the risk of diabetes and 
metabolic syndrome [50].  
Experimentally, it has been reported that ERα is the main ER isoform in liver [51], and 
many studies on mice models have attempted to elucidate the participation of ERs in 
hepatic metabolism. Previously, we have shown that in the livers of ERKO mice, there is 
increased glucose production and elevated expression of genes involved in hepatic 
triglyceride synthesis [52]. Studies using the ERα agonist, propyl pyrazole triol (PPT), 
showed increased expression of signal transducer and activator of transcription-3 (stat3) in 
the livers of wild-type mice [51], and the activation of hepatic Stat3 has been reported to 
have an antidiabetic effect [53]. A study on ob/ob mice showed that these mice respond to 
PPT with improved glucose tolerance and insulin sensitivity in association with suppression 
of mRNA levels of  glucose-6-phosphatase (g6p) and vLDL receptor [54]. Similarly, these 
ERα-mediated effects of E2 are also shown in HFD mice [55]. 
Hepatic inflammation is considered as a pathogenic feature of insulin resistance. Treatment 
of WT, ERKO and BERKO mice with an inflammatory inducer, interleukin (IL) 1β and E2, 
showed that E2 suppressed the expression of cytokines and transcription factors in WT and 
BERKO mice, but not in ERKO mice, suggesting that ERα mediates E2-induced anti-
inflammatory effect in the liver [56]. 
Finally, ERβ has metabolic functions in the liver also. BERKO mice fed HFD had lower 
triglyceride levels and improved hepatic insulin sensitivity in association with increased 
insulin mediated-Akt phosphorylation, suggesting that ERβ has a diabetogenic role [57].  
1.4.4 Estrogen and skeletal muscle 
Skeletal muscle is the main organ responsible for glucose uptake in response to binding of 
insulin to its receptor in the skeletal muscle. Insulin activates a phosphorylation cascade 
that involves several proteins and leads to the translocation of GLUT4 from the cytoplasm 
to the cell membrane and allows transport of glucose into the cell. In the physiological 
range, E2 is beneficial for muscular insulin sensitivity, but low or high levels of E2 are 
linked to insulin resistance [58]. 
Skeletal muscle expresses both ERs, and in mice ERβ is the main isoform [59, 60]. 
Previously, it has shown that in BERKO mice, both glucose tolerance and insulin release 
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are normal or better than in wild-type mice, and in the absence of ERα there is decreased 
glucose uptake in muscle [52]. When ARKO male mice are treated with a selective ERβ 
agonist, diarylpropionitrile, there is a decrease in GLUT4 expression in muscle [59]. 
Tamoxifen has no effect on glucose tolerance in muscle in wild-type or BERKO mice, but 
in ERKO mice, tamoxifen increased GLUT4 expression and improved insulin sensitivity 
[45]. In the same context, treatment of a myoblast cell line with PPT increased GLUT4 
translocation to the cell membrane [61]. Treatment of ovariectomized rats with PPT also 
increased glucose uptake due to high GLUT4 expression in skeletal muscle [62]. In 
summary, these data suggest an inhibitory action of ERβ and stimulatory role for ERα on 
GLUT4 expression. 
1.4.5 Estrogen and the pancreas 
ERs are key players in the physiology and pathology of the pancreas.  They have essential 
and important roles in the proliferation, differentiation and survival of β cells, in addition to 
the regulation of insulin synthesis and release. Both ERs have been demonstrated in the 
nucleus and cell membrane of β cells [63]. A study performed to confirm the role of ERs in 
the regulation of pancreatic β cell function showed that E2 increased insulin secretion and 
reduced glucose plasma levels through both classical transcriptional activation, and via a 
non-classical pathway that involved membrane ERs; the classical pathway was suppressed 
by ER antagonists, whilst the non-classical pathway was not [63] 
In BERKO mice, no changes have been observed in insulin or glucose levels, but increased 
islet size has been reported, suggesting the importance of ERβ in regulating islet size in 
vivo [45]. We have shown previously that ERKO mice have increased fasting insulin and 
glucose levels which may link the absence of ERα to islet dysfunction [52]. Furthermore, 
the importance of ERα is illustrated in studies of islets isolated from wild-type, ERKO, and 
BERKO mice. When islets were treated with E2, a strong insulin secretion was reported in 
cells from wild type and BERKO mice, but not in those from ERKO mice.  
E2 exerts anti-apoptotic effects on β cells [64]. In ARKO mice, there is increased apoptosis 
of β cells, and treatment of these mice with E2 prevented apoptosis and avoided the 
development of diabetes. Similarly, in ERKO mice, the protective effects of E2 were 
reduced, and based on this, ERα appears to protect β cells against apoptosis [64].  
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1.5 INFLAMMATION  
1.5.1 Definition and classification 
Inflammation is a vascular and cellular response which protects against stimuli of cell 
injury. It is classified as either acute or chronic (Table 2), and is mediated through chemical 
mediators which are released by host inflammatory cells [65].  
Table 2: Acute vs. chronic inflammation  
Inflammation Acute  
 
Chronic  
Duration Hours  
 
 
 
 
Days (prolonged)  
Cellular events mediated 
by  
Neutrophils  
 
 
 
 
Monocytes and macrophages 
Eosinophils: parasitic 
infection  
Lymphocytes: viral disease  
Vascular events 
 
 
 
 
 
Classical vascular response 
without angiogenesis 
Classical vascular response 
with angiogenesis  
Outcome and fate  Resolution and repair, or 
progress to chronic 
Resolution in association 
with tissue remodeling and 
repair, or it persists and 
associated with scarring, 
systemic dysfunctions and 
homeostasis loss  
 
1.5.2 Inflammatory cells and mediators  
Inflammation is mediated by cellular infiltration, consisting of mainly neutrophils in acute 
inflammation, and by macrophages in chronic inflammation. These cellular events are 
triggered by chemical mediators, and they are classified into two main categories (Figure 
5): cell-derived mediators and plasma-derived mediators [65]. Cell-derived mediators are 
released by leukocytes, macrophages, lymphocytes, endothelial and mast cells and include: 
vasoactive amines, arachidonic acid derivatives, cytokines and nitric oxide. Plasma-derived 
proteins are released mainly by liver and include: kinin, complements, coagulation protein 
and fibrinolytic protein  [65]. All of these different mediators are responsible for the 
cardinal/external features of inflammation: heat, redness, swelling, pain, and loss of 
function.  
Cytokines include polypeptides such as interleukin (IL) and tumor necrosis factor (TNF), 
and play an essential role as pro-inflammatory (IL1, IL6) and anti-inflammatory (IL-10) 
mediators. Arachidonic acids are metabolized by two metabolic pathways: cyclooxygenase 
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and lipoxygenase [65]. As a result of cyclooxygenase, different prostaglandins and 
thromboxane A2 are formed and lead to different vascular/platelets events [65]. The 
coagulation factor XII (Hageman factor) typically initiates the actions of plasma-derived 
mediators through the activation of four cascades: fibrinolysis, coagulation, kinin and 
complement system [65].      
 
Figure 5: inflammatory mediators 
 
1.5.3 Anti-inflammatory mechanisms  
Although inflammation is a defense mechanism against detrimental stimuli and initiates 
repair, the inflammatory process and subsequent repair/remodeling events can cause harm 
and complications. Thus, mediators of inflammation and their molecular mechanisms of its 
action are the focus of studies with the goal of preventing and treating chronic diseases 
associated with inflammation [65]. Glucocorticoids/steroids and non-steroidal anti-
inflammatory drugs are the most frequent used treatments (Figure 6).  
The anti-inflammatory effects of glucocorticoids involve molecular mechanisms which 
mainly result in the suppression of phospholipase [65]:  these include direct effects on gene 
expression, or indirect effects through interaction with transcription factors. However, since 
the anti-inflammatory mechanisms of glucocorticoids involve interruptions in other 
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physiological-molecular cascades, this treatment modality is accompanied by severe 
systemic side effects [66].  
Non-steroidal anti-inflammatory drugs suppress cyclooxygenase 1and 2 selectively and 
non-selectively with less complications, compared to steroids [67]. Using of non-steroidal 
treatments has been reported to show positive effects on some chronic diseases associated 
with mild degrees of inflammation, such as improved glycemic control and reduced HbA1c 
in diabetic patients [68].  
Finally, physical exercise has been reported to suppress inflammation through myokines, 
for example IL15, which is released by muscles [69] . In addition, the coagulation factor 
XII has been suggested to be a target to reduce thrombosis and inflammation [70].  
 
Figure 6: Anti-inflammatory mechanisms  
1.5.4 Inflammation and the role of estrogen 
Obesity is one of the clinical manifestations of metabolic syndrome, and  is associated with 
chronic low-grade inflammation in the liver and adipose tissue, features which are 
recognized as an important link between obesity and insulin resistance [71]. Menopause is 
considered to be an additional risk factor for obesity in females, compared with males [72]. 
A deficiency of circulating estrogen levels is associated with a shift towards an abdominal 
fat distribution which predisposes women to metabolic syndrome and T2D [73, 74]. The 
antidiabetic effects of E2 and ERT have been demonstrated by various clinical studies [75-
77], and also by experimental studies [19, 78, 79]. However, the changes in the immune 
system which occur as result of estrogen deficiency and during subsequent ERT are not 
fully clear [80, 81]. For example, clinical trials [82, 83] have reported that ERT results in 
increases of serum (c-reactive protein) CRP levels in postmenopausal women. Similarly, 
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studies showed that E2 treatment led to increases in the levels of CRP, together with 
concomitant increases in the levels of IL6, in healthy postmenopausal women [84]. In 
contrast, it has been shown that E2 suppresses circulating CRP levels in postmenopausal 
women with T2D [85]. Experimentally, elevated levels of plasma IL6 have been reported 
previously in ovariectomized mice due to fatty feeding, while plasma levels of TNFα were 
unchanged [86].  One of the suggested explanations, the aging process and the onset of 
menopause, may be relevant to the determination of the exact role of E2 on inflammation, 
since it has been shown E2 inhibits inflammation in cells derived from young mice, but not 
in cells from aged mice, supporting an age-specific action for E2 [87, 88]. 
 
1.6 TYPE 2 DIABETES  
1.6.1 Background  
Generally, about 10% of all diagnosed adult diabetics are categorized as having type l 
diabetes (T1D), while T2D accounts for 80% of all diagnosed diabetes [2]. In addition, 
there are other types of diabetes (10%) such as mitochondrial diabetes and gestational 
diabetes [2].  
T1D develops because of a loss of insulin production due to the autoimmune destruction of 
pancreatic beta cells. Included in the T1D category is latent autoimmune diabetes of the 
adult, which is a slowly progressing autoimmune form of diabetes.  In the other hand, 
development of T2D is due to insulin resistance and β-cell dysfunction [2].  
According to the 2006 WHO recommendations for the diagnostic criteria for diabetes, 
diabetes is diagnosed by any of the following [89]: (1) fasting blood glucose level ≥7.0 
mmol/l  (≥126 mg/dl) with no caloric intake for eight hours, (2) Two-hours glucose level 
≥11.1 mmol/l  (≥200 mg/dl), (3) HgA1c is  ≥6.5 %.  
1.6.2 Pathogenesis of type 2 diabetes 
T2D is a heterogeneous disease with complex etiological factors that are caused by both 
genetic inheritance and environmental factors. T2D is characterized by an impairment of 
insulin secretion due to β-cell dysfunction, and by resistance to the actions of insulin in 
target tissues [2].  
During the development of the disease, as a compensatory mechanism, the β-cell 
population responds to decreased tissue sensitivity to insulin by increasing its function to 
maintain glucose homeostasis. However, this occurs only up to a certain limit, after which 
the β-cells fail and a hyperglycemic state develops. There is thus a progressive deterioration 
of both function and mass of the β-cell population.  Several acquired factors, in parallel 
with a genetic predisposition, can affect β-cell function and survival. Among the acquired 
factors, both glucotoxicity and lipotoxicity can lead to increased apoptosis and a number of 
molecular changes [2].  
Insulin resistance is defined as the inability of insulin to produce its known biological 
actions at normal circulating concentrations. Along with T2D, insulin resistance is also a 
common feature of several disorders including obesity, metabolic syndrome and 
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nonalcoholic fatty liver disease (NAFLD). Insulin resistance leads to an impaired inhibition 
of the hepatic production of glucose and release of vLDL, decreases glucose uptake by 
adipose tissue and muscle, and increased lipolysis and circulating levels of free fatty acids 
[2].
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2 AIMS OF THE STUDY 
Estrogen loss in perimenopausal and postmenopausal women has been linked to several 
features of metabolic syndrome [73, 90], while ERT reverses these pathological and 
metabolic features [91]. However, ERT has been reported in basic and clinical research to 
associate with adverse effects including breast cancer and coagulopathy [92, 93]. Therefore, 
identification of the molecular mechanisms of estrogen’s beneficial effects would give the 
possibility to target them directly and to prevent the undesirable side effects.  
The overall aim of this study is to elucidate the molecular mechanisms underlying the 
beneficial antidiabetic effects of E2, and to investigate the molecular pathogenesis of 
metabolic disease that results due to loss of estrogen signaling. 
Specific aims were as follows:  
To identify the molecular mechanisms of body weight reduction and suppression of visceral 
adipogenesis by E2 (Paper 1) 
To investigate the molecular effects of E2 on hepatic AMPK and insulin signaling (Paper 2) 
To assess the effects of E2 on inflammatory processes which may be involved in the 
pathogenesis of metabolic disease (Paper 3) 
To trace the hepatic molecular pathogenesis of metabolic disorders associated with the 
interruption of estrogen signaling by ovariectomy (Paper 4) 
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3 MATERIAL AND METHODS 
3.1 EXPERIMENTAL MODELS AND ETHICAL CONSIDERATIONS   
Ethical permission for all of the work in this study has been approved by the local ethical 
committee at Karolinska Institute. Two models were employed in this study. The first is a 
long-term HFD feeding model of perimenopausal obesity which involves impaired glucose 
tolerance, elevated fasting blood glucose levels and insulin resistance. These features are 
accompanied by reduced plasma E2 levels, and E2 administration was shown to reconstitute 
E2 levels to those comparable with 4 month-old mice[19]. The second model is an 
OVX/SHAM-mouse model which mimics human menopausal ovarian hormone loss [20]. 
3.1.1 Perimenopausal model 
This model was employed in the first three papers: paper 1, paper 2 and paper 3. Female 
C57BL/6J mice of seven weeks of age were acclimatized for one week, and then housed at 
22–23°C in a 12 hr-12 hr light-dark cycle with free access to water and food. The mice were 
maintained until 12 months of age on either a low fat diet (LFD) containing 4.5 g fat/100 g 
(Lactamin, Sweden), or on an HFD containing 34.9 g fat/100 g (D12492, Research Diets, 
USA).  
3.1.2 Ovariectomized/SHAM model 
This model was used in the fourth paper. This model consists of ovariectomized (OVX) or 
sham-operated (SHAM) female C57BL/6JRj mice; the control SHAM mice underwent the 
same surgical procedure that was performed in OVX mice, except for ovariectomy. The mice 
were housed at 22–23°C in a 12 hr-12 hr light-dark cycle with open access to water and food. 
At the age of 11 weeks, the diet was changed from regular chow (Lactamin, Sweden) to 
either a control LFD containing 4.3 g fat/100 g (D12450, Research Diets, USA), or to an 
HFD containing 34.9 g fat/100 g (D12492, Research Diets, USA).  
3.2 TREATMENT PROCEDURES AND TISSUE PROCESSING  
Four different modalities of treatment, along with dietary intervention, were performed in the 
first three papers: paper 1, paper 2 and paper 3; whilst in paper 4, only a dietary intervention 
was performed. After nine months of housing with LFD or HFD feeding, mice were divided 
for treatment by one of four modalities, as follows: 
A) The first modality of treatment consisted of the subcutaneous injection of 0.05 mg/kg 
body weight E2 (Sigma-Aldrich, Sweden; LFD+E2 and HFD+E2 mice) prepared in vehicle, 
or with the same volume of vehicle (sesame oil/ethanol, 9:1; LFD, HFD mice).  
B) The second modality consisted of the subcutaneous injection 40 mg/kg body weight of 
sodium salicylate (SS) (Sigma-Aldrich, Sweden; LFD+SS, HFD+SS mice).  
C) The third modality was a combination of E2 and SS (LFD+E2+SS, HFD+E2+SS) at the 
dosages employed above.  
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D) The fourth modality aimed to study hepatic insulin signaling, in which the first treatment 
mentioned earlier was performed with an additional step during which mice in the LFD, HFD 
and HFD+E2 groups were given an intraperitoneal injection of either insulin (2 mU/g; 
Actrapid, Novo-Nordisk), or a similar volume of normal saline, after which all mice were 
sacrificed 5 minutes later.  
The first modality of treatment was applied in the studies which form the results in paper 1, 
paper 2 and paper 3. The second and third ones were used only in paper 3. The fourth 
modality, acute insulin treatment, was employed in paper 2 only. In all studies, mice were 
sacrificed by cervical dislocation after CO2 inhalation, and tissues were snap-frozen in dry ice 
and stored at -80ºC.  
3.3 INTRAPERITONEAL GLUCOSE TOLERANCE TEST, BLOOD GLUCOSE 
AND PLASMA INSULIN LEVELS 
In all of the studies, mice were fasted either overnight or for 8 hours, after which blood 
glucose levels were determined by glucometer (MediSence, Abbott Scandinavia, Sweden). 
Intraperitoneal glucose tolerance tests (IPGTT) were performed by intraperitoneal injection 
of glucose (2 g/kg body weight), after which blood glucose levels were assessed at different 
time points ranging between zero and 120 minutes. IPGTT was performed in all studies, and 
included in all papers. Plasma insulin levels were assessed by either an AlphaLISA kit 
(Perkin-Elmer, Sweden) in paper 1, or by a RIA kit (Novo Nordisk) in paper 2, according to 
the manufacturers’ protocols.  
3.4 TRIGLYCERIDE ASSAY 
Triglycerides were extracted from liver tissues and quantified using a Colorimetric Assay Kit 
(Cayman Chemical, BioNordika, Sweden). This assay was used in paper 2 and paper 4. 
3.5 BIOCHEMICAL ASSAYS FOR PLASMA LEVELS OF ADIPOKINES AND 
CYTOKINES 
In paper 3, the levels of cytokines, leptin and adiponectin were assayed. Plasma levels of 
inflammatory cytokines were measured using a BioPlex assay, according to the 
manufacturer’s protocol (Bio-Rad, Sweden). Plasma leptin and adiponectin levels were 
assayed by double-antibody RIA techniques (Linco Research, St. Charles, MO).  
3.6 MAGNETIC RESONANCE IMAGING (MRI) 
Using the perimenopausal model, MRI was employed in paper 1 to calculate the volumes of 
the visceral and subcutaneous fat depots in relation to the total body weight at the end of the 
one month of E2 treatment. LFD, HFD and HFD+E2 mice were anesthetized with 1.5-2.0% 
isoflurane in O2, with maintenance of body temperature. MRI was employed from the 
thoracic region down to pelvic region, and an average of 31 transverse slices was captured. 
Next, the image series were exported to ImageJ (1,47v, Wayne Rasband, NIH, USA) for 
analyses and calculations.   
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3.7 FROZEN SECTIONING, IMMUNOHISTOCHEMISTRY AND HISTOLOGY 
The visualization of morphology using histology, and the detection of specific antigens by 
employing IHC, are powerful techniques in the diagnostic and research laboratory. In paper 
1, both histology and IHC were used. For histology, sections were prepared from visceral 
adipose tissue by cryostat. The sections were stained with hematoxylin and eosin, and were 
visualized using a digital camera (10x and 40x magnifications, Leica DM 3000 LED, LAS 
Version 4.3.0). The purpose of this study was to assess the shape and size of adipocytes in the 
visceral adipose depot in different experimental groups.  
For IHC, frozen sections of 20 µm thickness were prepared from acetone-fixed adipose 
tissue. After blocking with 5% rabbit serum in antibody diluent (Cell Signaling Technology), 
the sections were incubated with anti-uncoupling protein 1 (UCP1) antibody (Abcam, UK) 
overnight.  After three washes with Tris-buffered saline (TBS), the sections were incubated 
with secondary antibody (Abcam, UK); immunostaining was enhanced by use of 
diaminobenzidine, after counterstaining with hematoxylin. Three images per section were 
collected using a digital camera (10x and 40X magnification, Leica DM 3000 LED, LAS 
Version 4.3.0). 
3.8 PROTEIN EXTRACTION AND WESTERN BLOT  
Using RIPA buffer, protein was extracted from frozen tissues and the protein concentrations 
were assayed according to a standard assay protocol (DC protein assay, Bio-Rad,USA). 
Protein samples were run on 10% ECL gels (Amersham, GE Healthcare, UK) and transferred 
to PVDF membranes. The membranes were probed with antibodies of interest to determine 
the presence and amount of the respective protein target.  
Western blotting is a robust and frequently used technique in molecular studies, and was 
employed in paper 1 and paper 2. The technique involves the electrophoretic separation of 
proteins, followed by a transfer step to membranes; following blocking, the membranes are 
probed with antibodies targeting specific proteins.  
3.9 NUCLEIC ACID EXTRACTION 
In addition to protein extraction, the extraction of biomolecules such as DNA and RNA is a 
crucial methodology in current molecular biological applications for analytical, diagnostic or 
preparative purposes [94]. Total RNA was prepared from visceral adipose tissue and liver 
using RNeasy Lipid kits (Qiagen, Sweden) and TRIzol reagent (Life Technologies Europe, 
Sweden), respectively. Extracted liver RNA was further cleaned using RNeasy Mini kits, and 
RNA from both tissues was treated with DNase I (Qiagen, Sweden). Genomic DNA was 
extracted from adipose tissue using a PureLink® Genomic DNA Mini Kit (Thermo Fisher 
Scientific, Sweden), according to manufacturer’s protocol for mammalian tissues. 
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3.10 REAL-TIME POLYMERASE CHAIN REACTION  
The real-time polymerase chain reaction is a laboratory diagnostic and investigative 
technique in molecular biology/pathology based on the polymerase chain reaction (PCR). It 
monitors the amplification of a targeted DNA molecule during the PCR, not at its end-point 
as in conventional PCR [95]. The real-time PCR was employed in all papers in this thesis. 
Using a 7300 Real-Time PCR system, all target mRNAs (papers 1, 2, 3 and 4) were assayed 
in triplicate 25 µl reactions which included the target Assay-on-Demand and 1x Master Mix 
(Applied Biosystems, Sweden). The same system was also used to assess the amplification of 
genomic DNA templates (paper 1) in a duplicate 25 µl reactions containing 1x SYBR Green 
Master Mix (Applied Biosystems, Sweden) and 50nM of each primer of interest 
(ThermoFisher Scientific, Sweden). 
3.11 EPIGENETIC STUDY  
Alterations in methylation levels is an epigenetic mechanism that has been linked to genetic 
alterations associated with diseases due to environmental factors [96]. In paper 1, analysis of 
methylation was achieved using an OneStep qMethyl Kit (Zymo Research, Irvine, CA, 
USA). The primers employed were designed using the web-based primer design tool 
Primer3.  Aliquots of 280 ng of each sample of DNA were placed into test and reference 
reactions containing 28 μl of 1x Test/Reference Reaction Premix in a final volume of 140 μl. 
The Test Reaction Premix contains methylation sensitive restriction enzymes, while the 
Reference Reaction Premix does not. The amplification of DNA templates was assessed by 
using a 7300 Real-Time PCR system as described above. 
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4 RESULT AND DISCUSSION 
4.1 17Β-ESTRADIOL SUPPRESSES VISCERAL ADIPOGENESIS AND 
ACTIVATES BROWN ADIPOSE TISSUE-SPECIFIC GENE EXPRESSION 
The aim of this study was to identify the molecular mechanisms which underlie the glycemic 
control and the anti-obesogenic effects of E2 in a perimenopausal mouse model fed on either 
LFD or HFD. Menopause is associated with an abnormal fat distribution and a central obesity 
which predisposes women to metabolic syndrome and T2D [73, 74]. ERT reduces T2D 
incidence [97], and the risk of T2D development in premenopausal women is less than men 
[98]. In experimental models, disruption of estrogen signaling by ovariectomy or by 
transgenic modification results in increased adiposity and weight gain [55, 99, 100]. 
Administration of E2 to these models promotes weight loss in association with the regulation 
of food intake [101] and increased energy expenditure [102]. In our study, HFD mice gained 
body weight and developed features of insulin resistance, including elevated levels of fasting 
blood glucose and plasma insulin and glucose intolerance due to HFD feeding for 10 months. 
Although E2 had no significant effects in LFD mice, E2 reduced body weight significantly in 
HFD+E2 mice in association with the improvement of the glycemic control. The reduction of 
body weight in HFD+E2 mice was observed from the day 10, which is consistent with 
previous reports [103, 104]. However, the E2-induced body weight effect was preceded by a 
reduction in food intake from the day 4.   
MRI studies showed that E2-induced weight loss is paralleled with significant reductions in 
the visceral adipose depot, without significant changes in the subcutaneous depots. These 
observations occurred in parallel with morphological changes in the adipocyte population 
form this depot, such that hypertrophied adipocytes were observed in HFD mice, whilst 
adipocytes in HFD+E2 mice were smaller and comparable in size to those of LFD mice. 
These observations support what has been concluded previously in E2-treated ovariectomized 
mice [105], and indicate that E2 induces a restoration of the insulin-sensitive phenotype in the 
visceral adipose tissue, since adipocyte size correlates inversely with insulin sensitivity in 
humans [106] and rodents [107]. In our study, the results of the IPGTT are consistent with 
these changes in visceral adipocyte morphology.  
Since hypertrophic changes of adipocytes have been linked to altered lipid metabolism [108], 
the mRNA levels of lipogenic and lipolytic genes in the visceral adipose depot were 
investigated. The results show that E2-induced reductions in adipocyte size involved the 
reduced expression of the lipogenic genes scd1 and fas, and increased expression of adipose 
triglyceride lipase pnpla2. Moreover, E2 suppressed the expression levels of the nuclear 
receptor nr2c2/tr4, which has been identified as a transcriptional regulator of lipogenic gene 
expression [109]. Low E2 levels have been linked to leptin insensitivity [110], and E2 
treatment of ovariectomized mice has been shown to promote leptin sensitivity [111]. 
Consistent with this, in the current report, E2 administration led to the downregulation of 
leptin transcript levels, whilst it upregulated that of leptin receptors. These results are 
considered as features consistent with the promotion of leptin sensitivity by E2 in HFD+E2, 
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and this is supported by the observed increases in stat3 mRNA levels, which is activated by 
leptin [112]. From another angle, stat3 has a role in the regulation of brown adipocyte 
differentiation and function [113], a fact which reflects the possibility of increased energy 
expenditure as a mechanism of E2-induced the loss of adiposity. Therefore, the expression of 
brown adipose -specific markers was assessed. The results show that the transcript of ucp-1 
and its protein levels were upregulated by E2. The expression of UCP-1 is known to be 
involved in the beiging of white adipose depots, including the visceral depot [114]. 
Additionally, the mRNA levels of the thermogenic gene dio-2, along with the brown adipose-
specific gene cpt1b [115], were increased significantly. Consistent with the upregulation of 
ucp-1 and dio-2 expressions, the expression of adrenergic receptor β3 (adrβ3), which is 
known to regulate UCP-1 during the thermogenic response [116] , was increased in the 
HFD+E2 group.  
It was observable that the effects of E2 were specific to chronic HFD exposure, and HFD 
feeding has been linked to epigenetic changes in methylation [117]. Thus, analysis of 
methylation was relevant to understanding the molecular events in HFD+E2 mice, and the 
results revealed that the up-regulation of expression of adrβ3 and dio-2 by E2 treatment was 
associated with the suppression of methylation levels. These results are supported by a 
previous report showing that methylation at specific sites within these genes results in 
decreased transcriptional activity [96].  
In conclusion, the anti-obesogenic effect of E2 on visceral adipose tissue results in 
improvement of glucose homeostasis in this mouse model of perimenopausal obesity. The 
anti-obesogenic effects include the suppression of visceral adipogenesis and the reduction of 
adipocyte size. This study provided a molecular explanation for these anti-obesogenic effects, 
including the activation of the lipolytic enzyme pnpla2, the suppression of lipogenic gene 
expression possibly through downregulating the expression levels of the transcriptional 
nuclear receptor nr2c2/tr4, and the induction of brown adipose tissue-specific gene 
expression via E2-dependent alterations in methylation levels (Figure 7). 
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Figure 7: Molecular mechanisms of antidiabetic effects of E2 on visceral adipose tissue (Paper 1) 
 
4.2 ACTIVATION OF HEPATIC AMPK BY 17Β-ESTRADIOL SUPPRESSES 
BOTH NUCLEAR RECEPTOR NR2C2/TR4 AND ITS DOWNSTREAM 
LIPOGENIC TARGETS, REDUCES GLUCONEOGENIC GENES AND 
IMPROVES INSULIN SIGNALING 
This study aimed to identify the hepatic mechanisms involved in the beneficial effects of E2 
on insulin sensitivity in the perimenopausal mouse model exposed to 10 months HFD 
feeding. Activation of hepatic AMPK is a known therapeutic mechanism for the 
improvement of hepatic insulin resistance [118, 119] resulting mainly from both lipid 
accumulation and increased hepatic gluconeogenesis [120, 121]. Therefore, it was of interest 
to assess whether the beneficial effects of E2 on glycemic control involve hepatic AMPK 
activation. In this study, phosphorylation of hepatic AMPK at Thr172 was significantly 
reduced in HFD mice, whilst E2 activated that in HFD+E2. In addition, activated AMPK 
suppresses hepatic lipogenesis via the inactivation of the ACC1 [118]. Consistent with this, 
the results of our report showed that the activation of AMPK is accompanied by a subsequent 
increase in the phosphorylation of ACC1 on Ser79, which ultimately inactivates this 
lipogenic enzyme.  Another mechanism through which activated hepatic AMPK reduced 
lipogenesis has been reported recently [109]. This study shows that inactivation of the nuclear 
receptor NR2C2/TR4 due to activation of hepatic AMPK by metformin suppresses 
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downstream lipogenic gene expression. In paper 2 presented here, E2 treatment of HFD+E2 
mice led to reductions in NR2C2/TR4 expression at both the mRNA & protein levels. This 
effect of E2 treatment has been reported previously by our group in adipose tissue (paper 1) 
[122]. These observations suggested that the expression of further downstream lipogenic 
genes, including scd1, fas and acc1, may also be reduced. Consistent with this, E2 treatment 
in HFD+E2 mice reduced the mRNA levels of these genes, and in addition, protein levels of 
ACC1 were reduced significantly.  Since lipid accumulation in the liver is described as a 
strong pathogenic factor which results in insulin resistance in this organ [120], our results 
suggest that the beneficial effects of E2 involve the hepatic AMPK-dependent inhibition of 
lipogenic gene expression via the inhibition of NR2C2/TR4 levels. This conclusion was 
supported by further assessment of hepatic triglyceride contents; as expected these molecular 
events induced by E2 treatment in HFD+E2 mice were accompanied by normalization of 
hepatic triglycerides which were increased significantly due to HFD feeding. Finally, the 
mRNA levels of hormone sensitive lipase (lipe) were suppressed in HFD mice, and E2 
treatment in HFD+E2 mice resulted in upregulated lipe expression; this suggests that E2-
induced reductions in hepatic triglyceride levels may not only be due to suppression of 
lipogenesis, but also with increased triglyceride mobilization via stimulation of lipe 
expression.  
Assessment of fasting blood glucose levels showed that HFD feeding resulted in elevated 
fasting blood glucose levels, and the beneficial effects of E2 in HFD mice involved 
normalization of this parameter. These observations indicate an involvement of hepatic 
gluconeogenesis, and therefore the transcript levels of some gluconeogenic genes were 
assayed. The results showed that E2 treatment of HFD+E2 mice resulted in suppression of 
the expression levels of glucose-6-phosphatase catalytic (g6pc) subunit, g6pt1, and pyruvate 
carboxylase. Expression levels of the latter two were upregulated in HFD mice and correlated 
with fasting blood glucose levels, whilst the expression levels of g6pc did not change and so 
did not correlate with elevated fasting blood glucose levels in HFD mice. These observations 
are supported by available studies in the literature. For example, it has been shown that the 
protein levels of the pyruvate carboxylase correlate significantly with plasma glucose levels 
[123]. Moreover, a lack of correlation between fasting blood glucose levels and the 
expression levels of g6pc has been reported formerly in patients with T2D [124]. However, it 
has been shown, firstly, that g6pc expression levels are suppressed by activated hepatic 
AMPK [125], and secondly, that g6pc is a direct gene for estrogen receptor α [54]. Our 
current results are supported by these two reports, since, firstly, the expression levels of g6pc 
were suppressed by E2 treatment in both LFD+E2 and HFD+E2 mice, and secondly, E2 
treatment activated hepatic AMPK, which may give a mechanistic explanation for the 
suppression of g6pc by E2 treatment.  
In fact, the beneficial effects of activated hepatic AMPK extend beyond the suppression of 
hepatic lipogenesis and gluconeogenesis. It has been demonstrated that the positive role of 
adiponectin on metabolic homeostasis is medicated through AMPK signaling via adiponectin 
receptors [126-128]. However, in this report, the results show no correlation between E2-
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induced activation of hepatic AMPK and the expression levels of adiponectin and its 
receptors. It has also been reported previously that E2 suppressed plasma levels of leptin in 
HFD+E2 mice [19], and in the current study, hepatic leptin receptor expression in HFD+E2 
was significantly increased.  
Since E2 treatment significantly normalized glucose levels before and during the IPGTT in 
HFD+E2 mice, these results together with other studies show that E2 treatment affects insulin 
tolerance positively [19, 129], suggesting that E2 improves insulin signaling. Thus changes in 
insulin-dependent phosphorylation of IRS-AKT-FOXO protein intermediates in the hepatic 
insulin signaling pathway were investigated. Insulin promotes the synthesis of glycogen, 
lipids and protein in the liver, and suppresses hepatic gluconeogenesis. Thus the IRS-AKT-
FOXO cascade has been investigated to study the pathogenesis of hepatic insulin resistance. 
For example, the double knockout of both hepatic Irs1 and Irs2 (L-DKO mice) interrupts 
insulin/food-induced phosphorylation of Akt and Foxo1, and results in hyperglycemia due to 
increased endogenous glucose production [130]. Similarly, knockout of both akt1 and akt2 in 
the liver (Akt-DLKO) results in the same diabetic phenotype as observed in L-DKO [131]. L-
DKO mice were employed in other studies involving further foxo1 gene knockout (L-TKO), 
which resulted in reversal of the diabetic and growth retardation features observed previously 
in L-DKO [132], suggesting FOXO1 activation has a role in development of diabetes. In our 
study, insulin-resistant HFD mice showed a reduced insulin-dependent phosphorylation of 
AKT2 and FOXO1. However, E2 treatment in HFD+E2 mice was associated with increased 
insulin-dependent phosphorylation of the signaling intermediates, in parallel with normalized 
hepatic triglyceride levels, and suppressed expression of gluconeogenic genes.   
In summary, improvements of glycemic control induced by E2 treatment in HFD+E2 mice 
are associated with multiple hepatic molecular mechanisms: E2 treatment induces activation 
of hepatic AMPK, which results in the suppression of hepatic lipogenesis via inhibition of 
NR2C2/TR4, and in the inhibition of gluconeogenesis through suppression of the transcript 
level of g6pc; finally, E2 treatment normalizes hepatic triglycerides through the suppression 
of lipogenesis and the activation of triglyceride mobilization. The summative effect of these 
events is the improvement of hepatic insulin signaling (Figure 8). 
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  Figure 8: Hepatic molecular mechanisms of antidiabetic effects of E2 (paper 2)  
 
4.3 17Β-ESTRADIOL REDUCES BODY WEIGHT AND IMPROVES GLYCEMIC 
CONTROL WITHOUT SUPPRESSION OF INFLAMMATORY MEDIATORS 
IN PLASMA, ADIPOSE TISSUE AND LIVER   
In the previous two studies, it was reported that administration of E2 in a perimenopausal 
mouse model resulted in reductions of body weight and improvements in glucose 
homeostasis. These effects were associated with various molecular mechanisms in the 
adipose tissue (paper 1) [122] and liver (paper 2) [133]. Furthermore, this model is mimics 
perimenopause-associated obesity and glucose intolerance, and it is known that obesity is 
associated with chronic low-grade inflammation in the liver and adipose tissue, a feature 
which is recognized as an important link between obesity and insulin resistance [71].  
The current study was performed to assess the extent to which the beneficial effects of E2 
involve alterations in inflammatory status. The antidiabetic effects of E2 and ERT have been 
demonstrated by various clinical studies [75-77], and also by experimental studies [19, 78, 
79]. However, the changes in the immune system which occur as result of estrogen deficiency 
and during subsequent ERT are a source of debate [80, 81]. Observational studies [134, 135] 
and clinical trials [82, 83] have reported that ERT results in increases of serum CRP levels in 
postmenopausal women. Similarly, studies have shown that E2 treatment led to increases in 
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the levels of CRP, together with concomitant increases in the levels of IL6 in healthy 
postmenopausal women [84]. However, other studies report contradictory findings. For 
example, it has been shown that E2 suppresses circulating CRP levels in postmenopausal 
women with T2D [85]. There is a lack of experimental studies which are consistent with 
these observations. However, elevated levels of plasma IL6 have been reported previously in 
ovariectomized mice due to fatty feeding, while plasma levels of TNFα are unchanged [86].   
In our study, no significant changes were observed with regard to the plasma levels of the 
cytokines IL1β, IL6, granulocyte-macrophage colony-stimulating factor (GM-CSF), or of the 
chemokine MCP1. In addition, the expression levels of various cytokines and pro-
inflammatory mediators were unchanged in the liver, irrespective of dietary intervention or 
E2 treatment; however, in the visceral adipose tissue, E2 treatment led to an upregulation of 
the expression levels of il1β, il6, toll-like receptor 2 (tlr2), inhibitor of nuclear factor kappa-B 
kinase subunit β (ikkβ) and histocompatibility 2 class II antigen A beta 1 (mhc2). These 
findings reflect the possibility that the antidiabetic actions of E2 in mice subject to chronic 
HFD exposure do not involve an anti-inflammatory action in insulin target tissues. 
Accordingly, the effects of a combination treatment of E2 and SS were studied to determine 
whether such a combination could lead to additive glycemic effects.  
SS is one of several nonsteroidal anti-inflammatory drugs which has been reported to 
suppress cyclooxygenase 2 non-selectively [67]. In addition, it has been shown clinically that 
high dose aspirin treatment improves glycemic parameters [136]. In the same context, use of 
the anti-inflammatory drug salsalate decreases HbA1c [68]. The results in paper 3 showed 
that SS treatment led to reductions in body weight and in fasting blood glucose levels, in 
parallel with the suppression of gluconeogenic gene expression. Conversely, SS treatment 
failed to improve glucose tolerance and, either alone or in combination with E2, failed to 
suppress the upregulation of pro-inflammatory mediators induced by E2 in visceral adipose 
tissue.  
Diet-induced obesity and inflammation-related disorders have been linked to abnormal 
plasma levels and altered expression of the adipokines leptin and adiponectin. Circulating 
leptin levels directly correlate with adipose tissue mass, and leptin controls appetite [137]. 
Mutation in the genes encoding leptin or its receptors results in prominent obesity in mice and 
humans [138, 139]. Experimentally, HFD feeding induces leptin mRNA and increases serum 
leptin levels, in parallel with insulin resistance and glucose intolerance. However, in both the 
current report and previous studies [19, 122, 133], we have shown that E2 suppresses leptin 
plasma and expression levels, and increases the mRNA levels of leptin receptor.  
The levels of adiponectin, unlike leptin, do not correlate with fat mass [140]. In the current 
report, E2 suppressed both plasma levels of adiponectin, and also its expression levels in the 
visceral adipose.The downregulation of adiponectin levels by E2 has been interpreted to be a 
detrimental effect of E2 treatment in a previous report [19]. Adiponectin has an anti-
inflammatory role through its inhibition of TNFα [141], IL6 and nuclear factor κB [142]. 
These actions of adiponectin may occur via induction of the anti-inflammatory cytokine IL-
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10 [143]. Consistent with these reports, the E2-induced suppression of adiponectin levels in 
the current study may underlie the apparent pro-inflammatory action of E2 via the 
suppression of il10 expression and the upregulated expression levels of il1β, il6, ikkβ and tlr2 
in the visceral adipose tissue of HFD+E2 mice.  
In conclusion, the local increased expression levels of pro-inflammatory mediators in visceral 
adipose, the unchanged plasma levels of these pro-inflammatory mediators, and their 
unaltered hepatic mRNA levels do not impact upon the positive actions of E2 on body 
weight, fasting blood glucose levels, and glycemic control. The reductions induced by E2 in 
plasma levels of adiponectin, and in its mRNA levels in adipose tissue, could explain the 
continued elevated expression levels of these mediators. The aging process and the onset of 
menopause may be relevant to the determination of the exact role of E2 on inflammation, 
since it has been shown E2 inhibits inflammation in cells derived from young mice, but not in 
cells from aged mice, supporting an age-specific action for E2 [87, 88]. Further studies 
employing mouse models in which chronic endotoxemia is induced at various ages will 
clarify these issues, and will provide the opportunity to study the promotion of insulin 
sensitivity by E2 in the presence of a chronic inflammatory state (Figure 9). 
 
Figure 9: Antidiabetic effects of E2 and inflammatory mediators (Paper 3) 
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4.4 OVARIECTOMY RESULTS IN A CONTINUOUS ACCUMULATION OF 
HEPATIC TRIGLYCERIDES AND THE UPREGULATION OF 
INFLAMMATORY MEDIATORS FOLLOWING SHORT-TERM EXPOSURE 
TO HIGH-FAT DIET         
The current study employs OVX and SHAM mice, which were fed on either LFD or HFD for 
3 days or 5 days. As reported previously, this feeding regime leads to features of NAFLD 
which result in hepatic insulin resistance due to Kupffer cell activation [144]. The goal of this 
study was to assess whether estrogens were able to regulate the effects of short-term HFD 
exposure with regards to the features of NAFLD.  
The continuous increase in the prevalence of obesity is associated with the rising incidence of 
NAFLD, which currently surpasses that of alcoholic liver disease [145, 146]. The 
pathogenesis of NAFLD is poorly understood, but the accumulation of hepatic triglycerides is 
considered as its main feature [147] since it may play a major role in the development of 
hepatic insulin resistance and T2D [120, 121]. Epidemiological studies have shown that the 
risk of NAFLD increases in postmenopausal women [47, 48], which is most likely due to the 
loss of the protective effects of E2, while ERT is associated with the reduced risk of NAFLD 
[48].  
In animal models, treatment of OVX mice with E2 reverses hyperglycemic changes due to 
ovariectomy [79], and protects them from HFD-induced hepatic insulin resistance [148]. 
Both elevated hepatic triglyceride content (paper 2) [133] and increased levels of endogenous 
glucose production [52, 55] are observed in chronic HFD–exposed perimenopausal mice and 
in ERKO mice. The restoration of insulin sensitivity and improved hepatic insulin signaling 
by E2 treatment is associated with the suppression of lipogenic gene expression through 
suppression of NR2C2/TR4 (paper 2) [133], which controls scd1 and fas expression [109], or 
via suppression of lxrα and its target srebp1 [19]. These effects of E2 treatment occurred in 
parallel with reduced hepatic triglyceride content (paper 2) [133]. The results here show that 
short-term HFD feeding in both SHAM and OVX mice result in increased mRNA levels of 
the lipogenic genes scd1, fas and acc1. However, the results of our study also show a novel 
observation in SHAM mice fed on an HFD, since in presence of estrogen, there was a 
transient upregulation of these lipogenic genes and the transcription factors regulating their 
expression, lxrα and srebp1, after 3 days of HFD feeding, but then their suppression after 5 
days of HFD feeding. This pattern of expression changes was not observed in OVX mice fed 
on an HFD, in which the upregulated expression of lipogenic genes and of lxrα and srebp1 
increased progressively from 3 to 5 days. Furthermore, the expression levels of nr2c2/tr4 
were upregulated in both OVX mice fed on an LFD, and in OVX mice fed on HFD, 
regardless of diet. This suggests that the expression of nr2c2/tr4 is at least partly controlled 
through estrogen signaling.  
In the present study, the mRNA levels of gluconeogenic genes, including g6pc, g6pt1 and 
pyruvate carboxylase, were assessed. No correlation was found between g6pc and the 
elevated levels of fasting blood glucose levels among the different groups, and this finding is 
consistent with other studies which reveal the lack of correlation between hepatic G6PC 
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expression levels with fasting glucose levels [124, 133]. However, the expression levels of 
pyruvate carboxylase do correlate with increased hepatic glucose production in OVX mice 
fed on an HFD, as has been shown before [123]. Previously, expression levels of g6pc, g6pt1 
and pyruvate carboxylase were suppressed significantly by E2 treatment of HFD+E2 mice 
(paper 2) [133].  
The pathogenesis of NAFLD is known to involve both lipid accumulation in the liver and 
hepatic inflammation [149]. NAFLD-induced hepatic inflammation is characterized by 
increased hepatic production of pro-inflammatory cytokines [150]. In our study, HFD feeding 
for 5 days resulted in increased mRNA levels of the macrophage marker cd68, regardless of 
whether the mice were OVX or SHAM, suggesting the lack of any interaction between 
estrogen signaling and the expression of this gene. Meanwhile, tlr2 expression levels were 
upregulated in OVX mice fed on either an LFD or an HFD, suggesting the presence of an 
interaction between estrogen signaling and tlr2 expression. TLR2 signaling has been reported 
to contribute to the adverse effects of HFD feeding in mice, and TLR2-deficient mice are 
protected from HFD-induced insulin resistance [151].  
Collectively, estrogens appear to suppress features of hepatic insulin resistance resulting from 
short-term HFD exposure, firstly by counteracting the continuous accumulation of hepatic 
triglycerides, and secondly via the reduced expression levels of gluconeogenic genes. OVX 
mice gained weight, had elevated fasting blood glucose levels, increased hepatic triglycerides 
and increased expression levels of both nr2r2/tr4 and the pro-inflammatory tlr2, 
independently of dietary intervention (Figure 10). These observations were paralleled in 
OVX mice fed on an HFD by a continuous and progressive upregulation of lipogenic genes 
and their regulatory transcription factors, lxrα and srebp1. In contrast, SHAM mice fed on an 
HFD exhibited levels of hepatic triglycerides which were higher than SHAM mice fed on an 
LFD, but which were lower than those of OVX fed on an HFD. The latter observation may be 
due to an estrogen-driven downregulation of these lipogenic genes and transcription factors in 
SHAM mice after 5 days of HFD feeding, following their previous upregulation after 3 days 
of HFD feeding. Finally, although HFD feeding for 5 days resulted in increased mRNA levels 
of the macrophage marker cd68, regardless of whether the mice were OVX or SHAM, OVX 
fed on an HFD for 5 days had significant increases in the expression levels of the 
gluconeogenic pyruvate carboxylase, and upregulation of the pro-inflammatory gene il6 
(Figure 11). 
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Figure 10: Effects of ovariectomy on hepatic metabolism (Paper 4)  
 
Figure 11: Effects of ovariectomy on hepatic metabolism (Paper 4) 
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5 CONCLUSIONS 
This study aimed to elucidate the beneficial antidiabetic molecular mechanisms of E2, and 
the molecular pathogenesis of metabolic diseases that result due to estrogen signaling loss. 
The following points can be concluded:  
 The anti-obesogenic effects of E2 on visceral adipose tissue are associated with 
improvements in glucose homeostasis in this mouse model of perimenopausal obesity 
and insulin resistance. The anti-obesogenic effects include the suppression of visceral 
adipogenesis and the reduction of adipocyte size. This study provided molecular 
explanations for the anti-obesogenic effects of E2; including the activation of the 
lipolytic enzyme pnpla2, the suppression of lipogenic gene expression possibly 
through downregulating the expression levels of the nuclear receptor nr2c2/tr4, and 
the induction of brown adipose tissue-specific gene expression via E2-dependent 
alterations in methylation levels (Paper 1). 
 
 Improvements of glycemic control induced by E2 treatment in HFD mice are 
associated with multiple hepatic molecular mechanisms: E2 treatment induces 
activation of hepatic AMPK, which results in the suppression of hepatic lipogenesis 
via inhibition of NR2C2/TR4, and in the inhibition of gluconeogenesis through 
suppression of transcript levels of g6pc; E2 treatment also normalizes hepatic 
triglycerides through the suppression of lipogenesis and the activation of triglyceride 
mobilization; the summative effect of these events results in improvements in hepatic 
insulin signaling (Paper 2). 
 
 The local increased expression levels of pro-inflammatory mediators in visceral 
adipose, the unchanged plasma levels of these pro-inflammatory mediators, and their 
unaltered hepatic mRNA levels, do not impact upon the positive actions of E2 on 
body weight, fasting blood glucose levels, and glycemic control. The reductions 
induced by E2 in the plasma levels of adiponectin, and in its mRNA levels in adipose 
tissue, could explain the continued elevated expression levels of these mediators, and 
the supression of the anti-inflammatory il10(Paper 3). 
 
 Estrogen signaling appears to suppress features of hepatic insulin resistance resulting 
from short-term HFD exposure by opposing the continuous accumulation of hepatic 
triglycerides, and via reduced expression levels of gluconeogenic genes. Ovariectomy 
resulted in weight gain, elevation of fasting blood glucose levels, increased hepatic 
triglycerides and increases in expression levels of nr2r2/tr4 and the pro-inflammatory 
tlr2, independently of dietary intervention (Paper 4).  
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